Human Immunodeficiency Virus (HIV) Infection Clinical Trial
Official title:
Short-term Folinic Acid Supplementation Improves Vascular Reactivity in HIV-infected Individuals: a Randomized Trial
Objective: HIV infected individuals present a cluster of conditions that activate or injure
the vascular endothelium. The administration of folates may exert beneficial effects on
endothelial function in different populations at risk for cardiovascular disease. The aim of
the study was to determine the effects of 4 weeks folinic acid supplementation on forearm
vascular responses during reactive hyperemia in HIV-infected people under antiretroviral
therapy.
Methods: This was a prospective, randomized, double-blind, placebo-controlled trial to
compare the effects of 4 weeks daily ingestion of 5 mg folinic acid (n=15) or placebo
(n=15). Participants had to be on anti-retroviral therapy for at least 6 months before
enrollment, with undetectable viral load, and CD4 cell count > 200 cells/mm3. Vascular
function was evaluated with venous occlusion plethysmography at baseline and after 4 weeks,
for the determination of brachial artery reactive hyperemia, and after isosorbide dinitrate
administration
Design and participants This was a randomized, double-blind, placebo-controlled trial.
Eligible participants were individuals with known HIV disease according to Centers for
Disease Control revised criteria, aged 18 or over, on ART for at least 6 months, with
undetectable viral load (less than 50 copies/ml), and CD4 counts more than 200 cells/mm3.
Exclusion criteria were diabetes mellitus, any active infection, liver disease, renal
disease, history of cardiovascular disease, or uncontrolled hypertension, pregnancy, use of
illicit drug and mental illness that would compromise understanding and collaboration with
the study. Patients currently using tobacco, taking any dietary supplement (such as folic
acid or antioxidants) or women taking hormone replacement therapy were also excluded. All
medications in regular use were maintained throughout the study period. The protocol was
approved by the committee for ethics in research of the Hospital de Clínicas de Porto
Alegre, and all participants gave written informed consent.
Study settings The study took place at the HIV outpatient clinic of the Hospital de Clínicas
de Porto Alegre, a national reference center for HIV/AIDS in southern Brazil, from August
2009 to September 2011.
Interventions Participants were randomly assigned to a 4-week treatment with either folinic
acid (n=15) or placebo (n=15). The study supplementation regimens consisted of the capsules
containing 5 mg of folinic acid or placebo. Participants were provided with 1 bottle, which
contained 30 capsules. Subjects were instructed to take 1 capsule daily, in the morning.
Outcomes The primary outcome measure was assessment of brachial artery vascular responses
during reactive hyperemia. Secondary outcomes were the changes on the biochemical and
hemodynamic variables.
Vascular measurements After an overnight fast, the assessments were performed in a
temperature-controlled (20-22°C), quiet room, with subjects in the supine position.
Throughout the protocol, blood pressure (BP) and heart rate were measured in the dominant
arm using a calibrated oscillometric automatic device (Dinamap 1846 SX/P; Critikon, Florida,
USA). Forearm blood flow was measured by venous occlusion plethysmography (D.E Hokanson,
Washington, USA), in the nondominant limb, as previously described. In short, a rapid
inflator cuff was used in the upper arm to occlude venous outflow and hand circulation was
arrested by placing a cuff around the wrist. Reactive hyperemia (RH) was induced by placing
a cuff in the upper-arm at 250 mmHg, and releasing after 5 min. All flow recordings were
manually traced by an operator who was blinded to the groups, and time. The reproducibility
of flow measurements in our laboratory has intraday and interday coefficients of variation
of 6.9 and 9.2%, respectively. After 15 min of rest, 2.5 mg of sublingual isosorbide
dinitrate (Isordil®, Sigma, Brazil), was administered as an endothelium-independent
vasodilator. Five minutes later, endothelium-independent vasodilatation of the brachial
artery was measured.
Laboratory measurements All samples were obtained after an overnight fast, before and after
4 weeks of intervention. For each subject, total plasma homocysteine concentration, serum
folate, vitamin B12, glucose, creatinine, total cholesterol, high density lipoprotein
cholesterol (HDL-C), and triglycerides were measured. Serum folate and vitamin B12 levels
were measured by a competitive immunoassay using direct chemiluminescent technology (Bayer
ADVIA Centaur, Leverkusen, Germany). Plasma homocysteine levels were also measured by a
competitive immunoassay using direct chemiluminescent technology (IMMULITE 2000 Siemens,
Illinois, USA). Glucose, creatinine, total cholesterol, HDL-c, and triglycerides were
measured with standard laboratory methods.
Sample size and randomization Power calculations showed that a total number of 15
participants per group would be able to detect a change of 4ml/min/100ml in vascular
response during reactive hyperemia between groups, with a power of 80% and α=0.05. For
allocation of the participants, randomization was achieved by computer-generated list of
random numbers, and the investigators remained blind until the study was completed.
Participants were randomly assigned to placebo or folinic acid treatment groups. The
randomization procedure was performed in three blocks of 10 and was stratified according to
sex, to ensure a relatively equal number of men and women in each treatment group.
Folinic acid and placebo capsules were indistinguishable in shape, size, as well as color.
They were pre-packed in identical bottles and consecutively numbered for each patient,
according to the randomization schedule. Supplements were coded so that neither the
investigators nor the participants were aware of the contents. A person not affiliated with
the study was the only one entrusted with the identification code for the individually
wrapped bottles of capsules.
Statistical analysis All variables were tested for normal distribution with the
Kolmogorov-Smirnov test. Normally distributed variables are expressed as mean ± SEM.
Variables non-normally distributed are presented as median (25th-75th percentiles). Baseline
comparisons of group characteristics were carried out by unpaired t-test or Mann-Whitney U
test. To compare responses after 4 weeks of intervention, a two-way analysis of variance
(ANOVA) for repeated measures (group, time, and interaction) was used. Associations between
changes in serum folic acid and changes in RH and associations between changes in plasma
homocysteine and changes in RH were evaluated by Spearman's rank correlation coefficient. A
two-tailed P value of less than 0.05 was considered as statistically significant.
;
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02715700 -
Effects of Doravirine (MK-1439) on Methadone Pharmacokinetics in Methadone-Maintained Participants (MK-1439-045)
|
Phase 1 | |
Completed |
NCT03667547 -
Safety, Tolerability, and Pharmacokinetics of Raltegravir (MK-0518) in Healthy Japanese Male Participants (MK-0518-851)
|
Phase 4 | |
Completed |
NCT01422330 -
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Etravirine Administered in Combination With Other Antiretroviral Agents in Antiretroviral Treatment-Experienced HIV-1 Infected Patients
|
Phase 4 | |
Active, not recruiting |
NCT05452616 -
Same-day Versus Rapid ART Initiation in HIV-positive Individuals Presenting With Symptoms of Tuberculosis
|
N/A | |
Completed |
NCT04515641 -
Single-Dose Islatravir in Moderate Hepatic Impairment (MK-8591-030)
|
Phase 1 | |
Not yet recruiting |
NCT06430905 -
Safety, Reactogenicity and Immunogenicity of HB-502 and HB-501 Versus Placebo in People With HIV on Suppressive ART
|
Phase 1 | |
Terminated |
NCT02818283 -
Soy Modulation of Immune Activation, LDL- Levels, and Lowering Inflammation by Pretzel Isoflavone Dietary Intervention
|
N/A | |
Completed |
NCT04303156 -
Pharmacokinetics of Islatravir in Participants With Severe Renal Impairment (MK-8591-026)
|
Phase 1 | |
Completed |
NCT00717067 -
Pharmacokinetics, Safety And Toleration Of Maraviroc Administered To Subjects With Various Degrees Of Renal Impaired And Normal Renal Function
|
Phase 4 | |
Recruiting |
NCT04375800 -
Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Ages 4 Weeks to <12 Years and <45 kg (MK-1439-066)
|
Phase 2 | |
Completed |
NCT00821535 -
Investigation Of Safety And Pharmacokinetics Following A Single Oral Dose Of 300 Mg Maraviroc In Healthy Male Japanese Volunteers
|
Phase 1 | |
Completed |
NCT03618511 -
Interventions to Improve HIV Antiretroviral Therapy Adherence
|
N/A |